Novartis has stopped a Phase-3 trial of the renin inhibitor, aliskiren, in patients with type 2 diabetes and renal impairment because of safety problems and evidence the drug wasn’t effective. Aliskiren was being studied in 8,606 patients globally. ---Subscribe to MedNous to access this article--- Company News
